All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
What do long-term data from the VIALE-A trial tell us about treatment with azacitidine plus venetoclax?
DiNardo discusses findings from the long-term follow-up of the VIALE-A trial presented at ASH, including the continued improved overall survival of patients treated with azacitidine plus venetoclax compared with azacitidine alone. Covering topics such as prognostic mutational features and European LeukemiaNet risk groups, DiNardo comments on how use of this combination therapy impacts patients with acute myeloid leukemia in the long term.
More about...
Your opinion matters
15 votes - 77 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox